Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 10/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.51 |
| ▸ | NPY1R | P25929 | 7/20 | 0.51 |
| ▸ | NPY2R | P49146 | 5/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862098 | 1.00 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL18048887 | 1.00 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL19862397 | 1.00 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL19862401 | 0.99 | NPY4R (0.53) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL25867315 | 0.96 | CCKBR (0.50) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL25867236 | 0.95 | NPY4R (0.49) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL19861965 | 0.95 | NPY4R (0.51) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL25867233 | 0.95 | OPRM1 (0.55) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL22563329 | 0.94 | NPY4R (0.49) | NPY4RNPY5RNPY1RNPY2RREN | |
| SCHEMBL24147042 | 0.92 | NPY4R (0.51) | NPY4RNPY5RNPY1RNPY2RREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292362-A1 | CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | STEALTH BIOTHERAPEUTICS INC. | 2021-09-23 | — | — | US | disclosed |
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-04-28 | — | — | US | disclosed |
| US-20180044378-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044378-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | NPY4R 135/4885NPY5R 246/4885NPY1R 140/4885 |
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | NPY4R 135/4885NPY5R 246/4885NPY1R 140/4885 |
| US-20210292362-A1 | CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | MITF, PEPD, HLA-DRB1 | NPY4R 1097/4885NPY5R 1624/4885NPY1R 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.